Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
Abstract
SGLT2 inhibitors form a new class of hypoglycemic drugs. Despite of the pharmacodynamic profile, at the moment the opinion about their safety is controversial. This is due to increased number of reports given by FDA and EMA on the risk of serious adverse reactions - ketoacidosis, which is not specified in the instruction as a possible adverse effects. Ketatsidosis in patients with type 2 diabetes on therapy with SGLT2 inhibitors was appeared at moderately elevated glucose levels (200 mg/dL/11.1 mmol/L). The article deals with reports of ketoacidosis, caused by inhibition of SGLT2 and describes the alleged internal pathophysiological mechanisms associated with its development.
About the Authors
T. M. Bukatina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
A. S. Kazakov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
N. Yu. Velts
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
M. A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
E. Yu. Kolesnikova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
R. N. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
B. K. Romanov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Jung ChH, Jang JE, et al. A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes Metab J. 2014; 38(4): 261–273.
2. Ushkalova EA. A new class of antidiabetic drugs—ingibitors of sodium-glucose cotransporter. Farmateka. 2013; 16: 33–36.
3. Gorodetskiy VV, Gorodetskaya GI, Shikh EV et al. Opportunities for pharmacological modulation cytochrome P450 isoenzymes metabolizing sulfonylurea derivatives. Scientific Centre for Evaluation of Medicinal Products Bulletin.2014; 4: 22–26.
4. Nurbekova AA. Kanagliflozin—a new drug for the treatment of diabetes. Medicine. 2015; 12: 53–62.
5. Strojek KH, Yoon KH, Hruba V et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24- week, double-blind, placebo- controlled trial. Diabetes Obes Metab, 2011; 13: 928–38.
6. Matthews DR, Fulcher G, Perkovic V et al. Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added- on to insulin therapy +/– oral agents in type 2 diabetes [abstract 764]. Diabetologia. 2012; 55: 314.
7. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010; 5:133–41.
8. Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev, 1994. 74:993–1026.
9. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev, 2011; 91:733–94.
10. Santer R, Kinner M et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol, 2003; 14:2873–82.
11. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010; 5:133–41.
12. State Register of Medicinal Products. Canagliflozin, dapagliflozin, empagliflozin. Instructions for use. [Electronic resource]: URL: http://www.grls.rosminzdrav.ru/grls.aspx/
13. Lamos EM, Younk LM, Davis SM. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol, 2013; 9(6): 763–75.
14. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes, 2012;5:313–27.
15. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab, 2015;100(8): 2849–52.
16. Surya PR, Wilding JP. SGLT2 inhibition and ketoacidosis — should we be concerned?, Br J Diabetes Vasc Dis. 2015;15:155–158.
17. Sodium glucose co-transporter 2 (SGLT2) inhibitors. [Electronic source]. URL: http://www.who.int/medicines/publications/newsletter/en/
18. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections (03.12.2015 ã.). [Electronic source]. URL:http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm.
Review
For citations:
Bukatina T.M., Kazakov A.S., Velts N.Yu., Darmostukova M.A., Kolesnikova E.Yu., Alyautdin R.N., Romanov B.K. Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis. Safety and Risk of Pharmacotherapy. 2016;(2):33-39. (In Russ.)
Views:
1733
Email this article 